Trial Profile
Pharmacokinetic study of anti-hepatits C virus treatment with ombitasvir, paritaprevir, ritonavir, with or without Dasabuvir, in subjects with renal impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2016
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 22 Jul 2016 New trial record
- 07 Jul 2016 Results published in the Clinical Pharmacokinetics